Galecto reaps $64M to bring lead drug across IPF finish line, while making moves in NASH and beyond
Back in 2018, Hans Schambye raised $90 million to kick off a late-stage trial that could put Galecto Biotech’s lead drug on the final stretch toward approval for idiopathic pulmonary fibrosis. Two years later, he’s collected another $64 million to complete it.
The Copenhagen-based company has managed to continue recruitment for the 450-patient trial in spite of the pandemic, the CEO told Endpoints News, with data expected by the middle of 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.